| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vesicular Monoamine Transport Proteins | 33 | 2024 | 47 | 6.720 |
Why?
|
| Sesquiterpenes | 34 | 2021 | 90 | 6.620 |
Why?
|
| Receptors, Nicotinic | 47 | 2018 | 72 | 6.380 |
Why?
|
| Lobeline | 34 | 2024 | 40 | 6.160 |
Why?
|
| Antineoplastic Agents | 34 | 2021 | 1232 | 6.060 |
Why?
|
| Indoles | 33 | 2020 | 280 | 5.880 |
Why?
|
| Nicotinic Antagonists | 38 | 2018 | 45 | 5.580 |
Why?
|
| Dopamine | 43 | 2024 | 167 | 5.000 |
Why?
|
| Structure-Activity Relationship | 63 | 2021 | 396 | 4.100 |
Why?
|
| Nicotine | 38 | 2018 | 180 | 3.850 |
Why?
|
| Molecular Structure | 54 | 2021 | 320 | 3.610 |
Why?
|
| Rats | 92 | 2024 | 3162 | 2.910 |
Why?
|
| Drug Screening Assays, Antitumor | 25 | 2021 | 136 | 2.680 |
Why?
|
| Quaternary Ammonium Compounds | 15 | 2011 | 29 | 2.570 |
Why?
|
| Animals | 156 | 2024 | 13526 | 2.480 |
Why?
|
| Quinuclidines | 13 | 2020 | 39 | 2.460 |
Why?
|
| Aza Compounds | 9 | 2020 | 14 | 2.360 |
Why?
|
| Cell Line, Tumor | 43 | 2021 | 1470 | 2.320 |
Why?
|
| Prodrugs | 18 | 2014 | 35 | 2.280 |
Why?
|
| NF-kappa B | 19 | 2021 | 327 | 2.250 |
Why?
|
| Dose-Response Relationship, Drug | 45 | 2021 | 1367 | 2.200 |
Why?
|
| Stilbenes | 7 | 2018 | 58 | 2.180 |
Why?
|
| Morphine Derivatives | 6 | 2021 | 28 | 2.060 |
Why?
|
| Naltrexone | 19 | 2018 | 70 | 1.980 |
Why?
|
| Cell Proliferation | 23 | 2021 | 1031 | 1.930 |
Why?
|
| Drug Design | 13 | 2020 | 121 | 1.820 |
Why?
|
| Radiation-Sensitizing Agents | 14 | 2020 | 50 | 1.810 |
Why?
|
| Piperidines | 6 | 2020 | 98 | 1.700 |
Why?
|
| Methamphetamine | 20 | 2024 | 190 | 1.690 |
Why?
|
| Picolines | 14 | 2018 | 15 | 1.650 |
Why?
|
| Morphine | 7 | 2021 | 103 | 1.630 |
Why?
|
| Nicotinic Agonists | 15 | 2018 | 54 | 1.490 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2016 | 208 | 1.490 |
Why?
|
| Rats, Sprague-Dawley | 52 | 2024 | 1544 | 1.470 |
Why?
|
| Membrane Transport Proteins | 8 | 2010 | 46 | 1.400 |
Why?
|
| Blood-Brain Barrier | 9 | 2010 | 51 | 1.390 |
Why?
|
| Dopamine Uptake Inhibitors | 8 | 2019 | 54 | 1.380 |
Why?
|
| Alkaloids | 4 | 2021 | 34 | 1.360 |
Why?
|
| Crystallography, X-Ray | 18 | 2012 | 155 | 1.330 |
Why?
|
| Binding Sites | 18 | 2021 | 373 | 1.310 |
Why?
|
| Molecular Docking Simulation | 10 | 2021 | 93 | 1.300 |
Why?
|
| Drug Delivery Systems | 12 | 2014 | 148 | 1.290 |
Why?
|
| Tobacco Use Disorder | 8 | 2018 | 174 | 1.280 |
Why?
|
| Receptor, Cannabinoid, CB1 | 6 | 2020 | 123 | 1.260 |
Why?
|
| Esters | 6 | 2017 | 19 | 1.240 |
Why?
|
| Tetrabenazine | 7 | 2015 | 14 | 1.230 |
Why?
|
| Humans | 126 | 2024 | 53230 | 1.220 |
Why?
|
| Ligands | 21 | 2020 | 203 | 1.180 |
Why?
|
| Barbiturates | 7 | 2020 | 17 | 1.160 |
Why?
|
| Receptor, Cannabinoid, CB2 | 4 | 2020 | 57 | 1.140 |
Why?
|
| Protein Binding | 26 | 2020 | 670 | 1.120 |
Why?
|
| Piperazines | 5 | 2024 | 125 | 1.120 |
Why?
|
| Models, Molecular | 15 | 2020 | 352 | 1.090 |
Why?
|
| Neurons | 10 | 2013 | 394 | 1.040 |
Why?
|
| Stereoisomerism | 20 | 2016 | 101 | 1.040 |
Why?
|
| Pyrimidines | 4 | 2018 | 205 | 1.030 |
Why?
|
| Cell Survival | 7 | 2016 | 600 | 1.020 |
Why?
|
| Analgesics, Opioid | 8 | 2018 | 622 | 1.020 |
Why?
|
| Thiophenes | 5 | 2015 | 45 | 1.010 |
Why?
|
| Analgesics | 5 | 2016 | 104 | 1.010 |
Why?
|
| Triazoles | 2 | 2018 | 114 | 0.980 |
Why?
|
| Pyridines | 6 | 2015 | 135 | 0.920 |
Why?
|
| Hematologic Neoplasms | 2 | 2017 | 101 | 0.890 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 71 | 0.870 |
Why?
|
| Pain | 8 | 2017 | 351 | 0.870 |
Why?
|
| Pyridinium Compounds | 7 | 2018 | 20 | 0.870 |
Why?
|
| Smoking | 8 | 2014 | 526 | 0.860 |
Why?
|
| Carboxylic Acids | 2 | 2017 | 18 | 0.840 |
Why?
|
| Amphetamine-Related Disorders | 10 | 2018 | 93 | 0.840 |
Why?
|
| Nuclear Proteins | 5 | 2020 | 250 | 0.840 |
Why?
|
| Antitubercular Agents | 5 | 2011 | 89 | 0.830 |
Why?
|
| Quantitative Structure-Activity Relationship | 5 | 2013 | 32 | 0.820 |
Why?
|
| Pancreatic Neoplasms | 8 | 2018 | 219 | 0.800 |
Why?
|
| Amyloid beta-Peptides | 2 | 2021 | 65 | 0.800 |
Why?
|
| Peptide Fragments | 2 | 2021 | 209 | 0.770 |
Why?
|
| Brain | 17 | 2021 | 1350 | 0.760 |
Why?
|
| Acetonitriles | 2 | 2016 | 7 | 0.760 |
Why?
|
| Male | 85 | 2024 | 27435 | 0.760 |
Why?
|
| Chromatography, High Pressure Liquid | 10 | 2017 | 333 | 0.760 |
Why?
|
| Pyrrolidines | 3 | 2013 | 65 | 0.750 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 8 | 2018 | 40 | 0.740 |
Why?
|
| Guanidines | 3 | 2013 | 28 | 0.740 |
Why?
|
| Smoking Cessation | 7 | 2018 | 325 | 0.740 |
Why?
|
| Narcotic Antagonists | 10 | 2018 | 150 | 0.740 |
Why?
|
| Acrylonitrile | 3 | 2007 | 3 | 0.710 |
Why?
|
| Molecular Conformation | 12 | 2012 | 66 | 0.710 |
Why?
|
| Tryptophan | 3 | 2011 | 89 | 0.710 |
Why?
|
| Receptors, Opioid, delta | 4 | 2018 | 25 | 0.710 |
Why?
|
| Skin Absorption | 15 | 2014 | 24 | 0.700 |
Why?
|
| Benzylamines | 1 | 2021 | 14 | 0.700 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 25 | 0.700 |
Why?
|
| Thiazoles | 2 | 2014 | 52 | 0.690 |
Why?
|
| Enzyme Inhibitors | 8 | 2019 | 371 | 0.690 |
Why?
|
| Cotinine | 3 | 2008 | 20 | 0.680 |
Why?
|
| Naphthalenes | 3 | 2019 | 121 | 0.680 |
Why?
|
| Oocytes | 7 | 2014 | 95 | 0.670 |
Why?
|
| Neuroprotective Agents | 2 | 2021 | 101 | 0.670 |
Why?
|
| Drug Discovery | 4 | 2021 | 94 | 0.670 |
Why?
|
| Chelating Agents | 2 | 2020 | 31 | 0.670 |
Why?
|
| Chemistry, Pharmaceutical | 8 | 2009 | 35 | 0.660 |
Why?
|
| Oxyquinoline | 1 | 2020 | 8 | 0.660 |
Why?
|
| Receptors, Opioid, mu | 3 | 2018 | 53 | 0.660 |
Why?
|
| Kinetics | 12 | 2017 | 607 | 0.660 |
Why?
|
| Psychotropic Drugs | 2 | 2011 | 79 | 0.650 |
Why?
|
| Imidazolidines | 2 | 2010 | 3 | 0.650 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 130 | 0.640 |
Why?
|
| Oxycodone | 2 | 2012 | 27 | 0.620 |
Why?
|
| Hydrogen Bonding | 9 | 2012 | 35 | 0.610 |
Why?
|
| Anti-Bacterial Agents | 3 | 2015 | 830 | 0.600 |
Why?
|
| Canavanine | 4 | 2003 | 4 | 0.600 |
Why?
|
| Aconitine | 8 | 2015 | 9 | 0.600 |
Why?
|
| Chitosan | 2 | 2011 | 42 | 0.590 |
Why?
|
| Tetrazoles | 1 | 2018 | 41 | 0.570 |
Why?
|
| Heart Diseases | 1 | 2021 | 221 | 0.570 |
Why?
|
| Corpus Striatum | 14 | 2015 | 47 | 0.560 |
Why?
|
| Tubulin Modulators | 2 | 2016 | 28 | 0.560 |
Why?
|
| Hydrazones | 2 | 2009 | 6 | 0.560 |
Why?
|
| Drug Stability | 11 | 2017 | 38 | 0.560 |
Why?
|
| Tubulin | 2 | 2015 | 22 | 0.560 |
Why?
|
| Durapatite | 2 | 2015 | 23 | 0.550 |
Why?
|
| Self Administration | 11 | 2024 | 91 | 0.550 |
Why?
|
| Heterocyclic Compounds | 2 | 2014 | 30 | 0.540 |
Why?
|
| Drug Carriers | 3 | 2015 | 68 | 0.540 |
Why?
|
| Synaptic Vesicles | 9 | 2015 | 20 | 0.540 |
Why?
|
| Drug Tolerance | 9 | 2019 | 60 | 0.540 |
Why?
|
| Vinyl Compounds | 2 | 2009 | 3 | 0.530 |
Why?
|
| Coumarins | 2 | 2014 | 9 | 0.530 |
Why?
|
| Succinates | 1 | 2017 | 3 | 0.530 |
Why?
|
| Needles | 4 | 2014 | 25 | 0.530 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 5 | 2017 | 45 | 0.530 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 338 | 0.520 |
Why?
|
| Bupropion | 5 | 2009 | 34 | 0.520 |
Why?
|
| Amides | 1 | 2017 | 36 | 0.520 |
Why?
|
| Thiadiazoles | 2 | 2020 | 18 | 0.510 |
Why?
|
| Cell Cycle | 4 | 2014 | 237 | 0.510 |
Why?
|
| Carbamates | 2 | 2014 | 16 | 0.500 |
Why?
|
| Tumor Cells, Cultured | 12 | 2018 | 441 | 0.490 |
Why?
|
| Apoptosis | 10 | 2018 | 1139 | 0.490 |
Why?
|
| Solubility | 11 | 2010 | 83 | 0.490 |
Why?
|
| Dioxanes | 1 | 2016 | 10 | 0.490 |
Why?
|
| Hypertension | 1 | 2021 | 554 | 0.480 |
Why?
|
| Kidney Diseases | 3 | 2009 | 230 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 5 | 2016 | 138 | 0.480 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2013 | 79 | 0.480 |
Why?
|
| Brain Chemistry | 5 | 2017 | 68 | 0.480 |
Why?
|
| Health Maintenance Organizations | 5 | 2014 | 19 | 0.470 |
Why?
|
| Mitosis | 2 | 2014 | 86 | 0.470 |
Why?
|
| Benzyl Compounds | 2 | 2006 | 3 | 0.470 |
Why?
|
| Quinoxalines | 4 | 2015 | 26 | 0.470 |
Why?
|
| Membrane Glycoproteins | 3 | 2005 | 238 | 0.460 |
Why?
|
| Kidney Failure, Chronic | 6 | 2014 | 210 | 0.460 |
Why?
|
| Benzodioxoles | 1 | 2016 | 40 | 0.460 |
Why?
|
| Models, Chemical | 7 | 2009 | 65 | 0.460 |
Why?
|
| DNA Breaks, Double-Stranded | 6 | 2020 | 76 | 0.450 |
Why?
|
| Drug Evaluation, Preclinical | 10 | 2017 | 142 | 0.450 |
Why?
|
| Vancomycin | 1 | 2015 | 91 | 0.450 |
Why?
|
| Anticonvulsants | 2 | 2009 | 133 | 0.450 |
Why?
|
| Mecamylamine | 5 | 2010 | 13 | 0.450 |
Why?
|
| DNA Cleavage | 1 | 2014 | 2 | 0.440 |
Why?
|
| Guaiacol | 2 | 2005 | 2 | 0.440 |
Why?
|
| Inhibitory Concentration 50 | 8 | 2019 | 75 | 0.440 |
Why?
|
| Mice | 26 | 2020 | 5982 | 0.440 |
Why?
|
| Choline | 7 | 2013 | 64 | 0.440 |
Why?
|
| Azetidines | 2 | 2015 | 7 | 0.430 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2012 | 186 | 0.430 |
Why?
|
| Ganglionic Stimulants | 3 | 2005 | 7 | 0.430 |
Why?
|
| Osteomyelitis | 1 | 2015 | 134 | 0.420 |
Why?
|
| DNA Repair | 6 | 2020 | 197 | 0.410 |
Why?
|
| Excipients | 2 | 2011 | 9 | 0.410 |
Why?
|
| Thiobarbiturates | 5 | 2018 | 22 | 0.390 |
Why?
|
| Chlorobenzoates | 1 | 2012 | 2 | 0.390 |
Why?
|
| Acetamides | 1 | 2012 | 19 | 0.380 |
Why?
|
| Phosphorylation | 6 | 2021 | 533 | 0.370 |
Why?
|
| Biological Availability | 7 | 2011 | 107 | 0.370 |
Why?
|
| Renal Dialysis | 4 | 2023 | 196 | 0.370 |
Why?
|
| Tritium | 7 | 2013 | 43 | 0.370 |
Why?
|
| Protein Structure, Tertiary | 4 | 2017 | 252 | 0.360 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 2014 | 250 | 0.360 |
Why?
|
| Prostatic Neoplasms | 5 | 2017 | 401 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 164 | 0.350 |
Why?
|
| NADH, NADPH Oxidoreductases | 4 | 2016 | 12 | 0.350 |
Why?
|
| Neoplasms | 5 | 2018 | 1334 | 0.340 |
Why?
|
| Bone and Bones | 2 | 2015 | 501 | 0.340 |
Why?
|
| Nasal Mucosa | 1 | 2011 | 19 | 0.340 |
Why?
|
| Isoquinolines | 1 | 2010 | 22 | 0.340 |
Why?
|
| Estrenes | 1 | 2010 | 11 | 0.330 |
Why?
|
| Xenopus | 4 | 2014 | 41 | 0.330 |
Why?
|
| Substance-Related Disorders | 4 | 2018 | 630 | 0.330 |
Why?
|
| Administration, Cutaneous | 11 | 2014 | 53 | 0.330 |
Why?
|
| Amines | 1 | 2010 | 38 | 0.330 |
Why?
|
| Phosphates | 1 | 2010 | 51 | 0.330 |
Why?
|
| Radioligand Assay | 5 | 2016 | 46 | 0.330 |
Why?
|
| Large Neutral Amino Acid-Transporter 1 | 1 | 2010 | 1 | 0.330 |
Why?
|
| Leukemia | 1 | 2011 | 67 | 0.320 |
Why?
|
| Models, Biological | 6 | 2017 | 737 | 0.320 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2009 | 45 | 0.320 |
Why?
|
| Neurotransmitter Transport Proteins | 1 | 2009 | 1 | 0.320 |
Why?
|
| Skin | 8 | 2010 | 419 | 0.320 |
Why?
|
| Sulfonamides | 3 | 2008 | 139 | 0.320 |
Why?
|
| Reward | 3 | 2011 | 119 | 0.310 |
Why?
|
| Cyclooctanes | 1 | 2009 | 3 | 0.310 |
Why?
|
| Luminol | 1 | 2009 | 1 | 0.310 |
Why?
|
| Dipeptides | 1 | 2009 | 21 | 0.310 |
Why?
|
| Area Under Curve | 6 | 2011 | 185 | 0.310 |
Why?
|
| Biphenyl Compounds | 1 | 2009 | 31 | 0.300 |
Why?
|
| Estradiol | 1 | 2010 | 215 | 0.300 |
Why?
|
| Pregnanolone | 2 | 2007 | 6 | 0.300 |
Why?
|
| Isomerism | 5 | 2013 | 23 | 0.300 |
Why?
|
| Insurance, Major Medical | 1 | 2009 | 2 | 0.300 |
Why?
|
| Nonlinear Dynamics | 2 | 2007 | 18 | 0.300 |
Why?
|
| Melphalan | 1 | 2010 | 180 | 0.300 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 90 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2016 | 1043 | 0.300 |
Why?
|
| Drugs, Investigational | 1 | 2009 | 14 | 0.290 |
Why?
|
| Rabbits | 5 | 2016 | 372 | 0.290 |
Why?
|
| Aniline Compounds | 1 | 2009 | 48 | 0.290 |
Why?
|
| Imidazoles | 1 | 2009 | 114 | 0.290 |
Why?
|
| Time Factors | 11 | 2019 | 2991 | 0.290 |
Why?
|
| Salts | 4 | 2010 | 7 | 0.290 |
Why?
|
| Oligopeptides | 1 | 2009 | 94 | 0.290 |
Why?
|
| Chemistry Techniques, Synthetic | 2 | 2020 | 21 | 0.290 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2008 | 71 | 0.290 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2008 | 48 | 0.280 |
Why?
|
| Radiation Tolerance | 6 | 2020 | 78 | 0.280 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 111 | 0.280 |
Why?
|
| 2,2'-Dipyridyl | 2 | 2007 | 3 | 0.280 |
Why?
|
| Rats, Inbred F344 | 8 | 2016 | 194 | 0.280 |
Why?
|
| Alcohol Deterrents | 2 | 2018 | 10 | 0.280 |
Why?
|
| Disease Models, Animal | 10 | 2018 | 1517 | 0.280 |
Why?
|
| Pyrazoles | 3 | 2008 | 123 | 0.270 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 2019 | 89 | 0.270 |
Why?
|
| Glioblastoma | 2 | 2021 | 101 | 0.270 |
Why?
|
| Tosyl Compounds | 1 | 2007 | 2 | 0.270 |
Why?
|
| Fentanyl | 1 | 2008 | 40 | 0.270 |
Why?
|
| Drug Combinations | 4 | 2021 | 138 | 0.270 |
Why?
|
| Benzylidene Compounds | 1 | 2007 | 4 | 0.270 |
Why?
|
| Bacteria | 1 | 2009 | 226 | 0.270 |
Why?
|
| Female | 31 | 2021 | 28782 | 0.270 |
Why?
|
| Adhesives | 1 | 2007 | 2 | 0.260 |
Why?
|
| gamma-Cyclodextrins | 1 | 2007 | 3 | 0.260 |
Why?
|
| Transcription Factor RelA | 3 | 2021 | 32 | 0.260 |
Why?
|
| Thiazines | 1 | 2007 | 3 | 0.260 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 1219 | 0.260 |
Why?
|
| beta-Cyclodextrins | 1 | 2007 | 15 | 0.260 |
Why?
|
| Small Molecule Libraries | 4 | 2018 | 66 | 0.260 |
Why?
|
| Metabolic Detoxication, Phase II | 1 | 2007 | 11 | 0.260 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 92 | 0.260 |
Why?
|
| Muscarinic Antagonists | 1 | 2007 | 24 | 0.260 |
Why?
|
| Behavior, Addictive | 3 | 2019 | 62 | 0.260 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2007 | 11 | 0.260 |
Why?
|
| Eye | 1 | 2007 | 29 | 0.250 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2007 | 46 | 0.250 |
Why?
|
| Temperature | 1 | 2007 | 165 | 0.250 |
Why?
|
| Serotonin Antagonists | 1 | 2006 | 33 | 0.250 |
Why?
|
| Dihydromorphine | 1 | 2006 | 1 | 0.250 |
Why?
|
| Codeine | 1 | 2006 | 4 | 0.250 |
Why?
|
| Lactones | 2 | 2021 | 25 | 0.250 |
Why?
|
| Sulfates | 1 | 2006 | 26 | 0.250 |
Why?
|
| Formamides | 1 | 2006 | 4 | 0.240 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 317 | 0.240 |
Why?
|
| Pharmaceutical Preparations | 1 | 2006 | 74 | 0.240 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 175 | 0.240 |
Why?
|
| Glucuronides | 2 | 2003 | 48 | 0.240 |
Why?
|
| Indicators and Reagents | 2 | 2002 | 36 | 0.240 |
Why?
|
| Indomethacin | 1 | 2006 | 36 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 868 | 0.240 |
Why?
|
| Anabasine | 1 | 2005 | 1 | 0.240 |
Why?
|
| Biological Transport | 5 | 2010 | 150 | 0.240 |
Why?
|
| Environmental Pollutants | 1 | 2007 | 110 | 0.240 |
Why?
|
| Tropanes | 1 | 2005 | 4 | 0.240 |
Why?
|
| Tongue | 1 | 2006 | 40 | 0.240 |
Why?
|
| HEK293 Cells | 3 | 2024 | 235 | 0.240 |
Why?
|
| Boron | 1 | 2005 | 2 | 0.240 |
Why?
|
| Mice, Nude | 10 | 2017 | 232 | 0.230 |
Why?
|
| Caffeine | 2 | 2003 | 64 | 0.230 |
Why?
|
| Ethacrynic Acid | 1 | 2005 | 3 | 0.230 |
Why?
|
| Central Nervous System | 2 | 2003 | 76 | 0.230 |
Why?
|
| Membrane Transport Modulators | 1 | 2005 | 6 | 0.230 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 867 | 0.230 |
Why?
|
| Glaucoma | 1 | 2005 | 39 | 0.220 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2005 | 108 | 0.220 |
Why?
|
| Sulfones | 1 | 2004 | 24 | 0.220 |
Why?
|
| Hydrazines | 1 | 2004 | 19 | 0.220 |
Why?
|
| Cell Line | 6 | 2016 | 1016 | 0.210 |
Why?
|
| Benzoquinones | 1 | 2004 | 33 | 0.210 |
Why?
|
| Central Nervous System Stimulants | 3 | 2018 | 201 | 0.210 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2003 | 2 | 0.210 |
Why?
|
| Reference Standards | 3 | 2008 | 52 | 0.210 |
Why?
|
| Octanes | 1 | 2003 | 1 | 0.210 |
Why?
|
| Binding, Competitive | 6 | 2011 | 89 | 0.210 |
Why?
|
| Arginine-tRNA Ligase | 1 | 2003 | 1 | 0.210 |
Why?
|
| Benzazepines | 3 | 2015 | 20 | 0.210 |
Why?
|
| Blotting, Western | 5 | 2015 | 587 | 0.210 |
Why?
|
| Case Management | 1 | 2004 | 43 | 0.200 |
Why?
|
| Vesicular Biogenic Amine Transport Proteins | 4 | 2008 | 4 | 0.200 |
Why?
|
| Keratinocytes | 1 | 2004 | 91 | 0.200 |
Why?
|
| Toxins, Biological | 1 | 2023 | 7 | 0.200 |
Why?
|
| Administration, Sublingual | 3 | 2008 | 18 | 0.200 |
Why?
|
| Agmatine | 1 | 2003 | 1 | 0.200 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 330 | 0.200 |
Why?
|
| Hyperalgesia | 4 | 2018 | 39 | 0.200 |
Why?
|
| Rad51 Recombinase | 2 | 2020 | 29 | 0.190 |
Why?
|
| Behavior, Animal | 7 | 2016 | 187 | 0.190 |
Why?
|
| Reactive Oxygen Species | 4 | 2018 | 421 | 0.190 |
Why?
|
| Linear Models | 2 | 2017 | 287 | 0.190 |
Why?
|
| Rats, Wistar | 2 | 2021 | 192 | 0.190 |
Why?
|
| Models, Theoretical | 1 | 2004 | 180 | 0.190 |
Why?
|
| Polyethylene Glycols | 3 | 2015 | 95 | 0.190 |
Why?
|
| Conotoxins | 4 | 2015 | 7 | 0.190 |
Why?
|
| Chromatography, Liquid | 3 | 2008 | 245 | 0.180 |
Why?
|
| Aminobutyrates | 1 | 2002 | 3 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2016 | 274 | 0.180 |
Why?
|
| Cricetinae | 4 | 2016 | 190 | 0.180 |
Why?
|
| Disease Management | 1 | 2003 | 187 | 0.180 |
Why?
|
| Cricetulus | 3 | 2017 | 101 | 0.180 |
Why?
|
| Locomotion | 2 | 2019 | 79 | 0.180 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2011 | 250 | 0.180 |
Why?
|
| CHO Cells | 3 | 2017 | 124 | 0.180 |
Why?
|
| Cannabinoids | 2 | 2020 | 104 | 0.180 |
Why?
|
| Neoplastic Stem Cells | 2 | 2016 | 90 | 0.180 |
Why?
|
| Tumor Stem Cell Assay | 3 | 2016 | 16 | 0.180 |
Why?
|
| Guinea Pigs | 8 | 2010 | 75 | 0.180 |
Why?
|
| Electrophorus | 1 | 2021 | 5 | 0.180 |
Why?
|
| Butyrylcholinesterase | 1 | 2021 | 9 | 0.180 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 22 | 0.180 |
Why?
|
| Acetylcholinesterase | 1 | 2021 | 21 | 0.180 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2018 | 138 | 0.180 |
Why?
|
| Thermodynamics | 1 | 2021 | 34 | 0.170 |
Why?
|
| Cell Death | 3 | 2011 | 171 | 0.170 |
Why?
|
| Endothelium, Vascular | 3 | 2013 | 262 | 0.170 |
Why?
|
| Spectrophotometry, Ultraviolet | 5 | 2008 | 32 | 0.170 |
Why?
|
| Organoids | 1 | 2021 | 41 | 0.170 |
Why?
|
| Horses | 1 | 2021 | 49 | 0.170 |
Why?
|
| Lung Neoplasms | 4 | 2014 | 645 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2002 | 146 | 0.170 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2020 | 15 | 0.170 |
Why?
|
| Cannabinoid Receptor Agonists | 2 | 2020 | 50 | 0.170 |
Why?
|
| Benzene | 2 | 2011 | 8 | 0.170 |
Why?
|
| Hydrogen-Ion Concentration | 5 | 2009 | 169 | 0.170 |
Why?
|
| Lobelia | 2 | 2011 | 2 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2013 | 124 | 0.170 |
Why?
|
| Motor Activity | 7 | 2011 | 227 | 0.160 |
Why?
|
| Mass Spectrometry | 4 | 2014 | 294 | 0.160 |
Why?
|
| Protein Structure, Secondary | 1 | 2020 | 71 | 0.160 |
Why?
|
| Least-Squares Analysis | 2 | 2013 | 44 | 0.160 |
Why?
|
| Sulfuric Acids | 1 | 2020 | 8 | 0.160 |
Why?
|
| Cellulose, Oxidized | 1 | 2020 | 4 | 0.160 |
Why?
|
| Epilepsy | 1 | 2003 | 189 | 0.160 |
Why?
|
| DNA Damage | 3 | 2019 | 309 | 0.160 |
Why?
|
| Synaptosomes | 6 | 2019 | 13 | 0.160 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2014 | 35 | 0.160 |
Why?
|
| Serotonin | 3 | 2017 | 144 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 64 | 0.160 |
Why?
|
| Injections, Intravenous | 4 | 2007 | 129 | 0.160 |
Why?
|
| Alcohol Drinking | 2 | 2018 | 241 | 0.160 |
Why?
|
| Nanostructures | 1 | 2020 | 41 | 0.150 |
Why?
|
| Radiation-Protective Agents | 1 | 2020 | 69 | 0.150 |
Why?
|
| Vitamin E | 1 | 2020 | 76 | 0.150 |
Why?
|
| Signal Transduction | 6 | 2018 | 1748 | 0.150 |
Why?
|
| Pain Management | 2 | 2017 | 185 | 0.150 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 1222 | 0.150 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2016 | 47 | 0.150 |
Why?
|
| Ethanol | 2 | 2018 | 338 | 0.150 |
Why?
|
| Blood Pressure | 1 | 2021 | 518 | 0.150 |
Why?
|
| Aminopyrine | 1 | 2018 | 2 | 0.150 |
Why?
|
| Dactinomycin | 1 | 2018 | 24 | 0.140 |
Why?
|
| Cisplatin | 2 | 2018 | 282 | 0.140 |
Why?
|
| Growth Inhibitors | 1 | 2018 | 26 | 0.140 |
Why?
|
| RNA Helicases | 1 | 2018 | 30 | 0.140 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2008 | 46 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 45 | 0.140 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2018 | 60 | 0.140 |
Why?
|
| Substrate Specificity | 6 | 2016 | 197 | 0.140 |
Why?
|
| Hypesthesia | 1 | 2018 | 16 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 647 | 0.140 |
Why?
|
| Ketamine | 2 | 2008 | 62 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 83 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2016 | 136 | 0.130 |
Why?
|
| Protein Conformation | 5 | 2020 | 174 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 319 | 0.130 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2017 | 33 | 0.130 |
Why?
|
| Arginine | 3 | 2003 | 178 | 0.130 |
Why?
|
| Analgesia | 1 | 2017 | 14 | 0.130 |
Why?
|
| I-kappa B Proteins | 1 | 2017 | 15 | 0.130 |
Why?
|
| Intestinal Secretions | 1 | 2017 | 2 | 0.130 |
Why?
|
| Gastric Juice | 1 | 2017 | 6 | 0.130 |
Why?
|
| Diabetic Nephropathies | 1 | 2017 | 61 | 0.130 |
Why?
|
| GTP-Binding Proteins | 1 | 2017 | 85 | 0.130 |
Why?
|
| Diabetes Complications | 1 | 2018 | 124 | 0.130 |
Why?
|
| Electrophoretic Mobility Shift Assay | 6 | 2015 | 71 | 0.130 |
Why?
|
| Protein Subunits | 4 | 2015 | 77 | 0.130 |
Why?
|
| Flow Cytometry | 4 | 2011 | 400 | 0.130 |
Why?
|
| Chronic Disease | 5 | 2010 | 580 | 0.130 |
Why?
|
| Dengue Virus | 1 | 2016 | 13 | 0.120 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 237 | 0.120 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 32 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 405 | 0.120 |
Why?
|
| Cell Division | 2 | 2011 | 289 | 0.120 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2016 | 37 | 0.120 |
Why?
|
| Crystallization | 2 | 2007 | 33 | 0.120 |
Why?
|
| Fluorouracil | 2 | 2007 | 59 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 112 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 39 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 310 | 0.120 |
Why?
|
| Gliosarcoma | 1 | 2015 | 5 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5595 | 0.120 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 68 | 0.120 |
Why?
|
| Down-Regulation | 1 | 2017 | 344 | 0.120 |
Why?
|
| Dimerization | 1 | 2015 | 50 | 0.120 |
Why?
|
| Debridement | 1 | 2015 | 49 | 0.120 |
Why?
|
| Breast | 1 | 2016 | 87 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2013 | 26 | 0.120 |
Why?
|
| Oxidative Stress | 4 | 2013 | 819 | 0.120 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 62 | 0.120 |
Why?
|
| Acetylcholine | 4 | 2009 | 56 | 0.120 |
Why?
|
| Benzothiazoles | 1 | 2015 | 6 | 0.120 |
Why?
|
| Oxygen | 2 | 2008 | 338 | 0.110 |
Why?
|
| California | 3 | 2014 | 93 | 0.110 |
Why?
|
| Vestibular Nerve | 1 | 2015 | 5 | 0.110 |
Why?
|
| Benzofurans | 1 | 2015 | 19 | 0.110 |
Why?
|
| Colchicine | 1 | 2015 | 25 | 0.110 |
Why?
|
| Presynaptic Terminals | 1 | 2015 | 14 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2018 | 456 | 0.110 |
Why?
|
| Receptors, Cholinergic | 1 | 2015 | 14 | 0.110 |
Why?
|
| Motor Neurons | 1 | 2015 | 35 | 0.110 |
Why?
|
| Chronic Pain | 1 | 2017 | 183 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2010 | 148 | 0.110 |
Why?
|
| Glutathione | 2 | 2013 | 303 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2016 | 179 | 0.110 |
Why?
|
| HT29 Cells | 2 | 2016 | 13 | 0.110 |
Why?
|
| Stem Cells | 1 | 2016 | 189 | 0.110 |
Why?
|
| Enzyme Assays | 1 | 2014 | 10 | 0.110 |
Why?
|
| Neuralgia | 2 | 2012 | 44 | 0.110 |
Why?
|
| Drug Synergism | 5 | 2018 | 147 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 39 | 0.110 |
Why?
|
| Rubidium Radioisotopes | 2 | 2006 | 4 | 0.110 |
Why?
|
| Drug Interactions | 6 | 2011 | 196 | 0.110 |
Why?
|
| Deoxyribonuclease I | 1 | 2014 | 33 | 0.110 |
Why?
|
| Endodeoxyribonucleases | 1 | 2014 | 47 | 0.110 |
Why?
|
| Dihydro-beta-Erythroidine | 3 | 2009 | 4 | 0.110 |
Why?
|
| Tanacetum parthenium | 1 | 2014 | 3 | 0.110 |
Why?
|
| Thalamus | 2 | 2006 | 33 | 0.110 |
Why?
|
| G2 Phase | 1 | 2014 | 14 | 0.110 |
Why?
|
| Nucleus Accumbens | 3 | 2013 | 27 | 0.110 |
Why?
|
| Vascular Access Devices | 1 | 2014 | 23 | 0.100 |
Why?
|
| Computer Simulation | 2 | 2013 | 290 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 189 | 0.100 |
Why?
|
| Multienzyme Complexes | 1 | 2013 | 42 | 0.100 |
Why?
|
| Viscosity | 2 | 2010 | 8 | 0.100 |
Why?
|
| Dioxolanes | 1 | 2013 | 16 | 0.100 |
Why?
|
| Swine, Miniature | 2 | 2010 | 17 | 0.100 |
Why?
|
| Diet | 1 | 2018 | 610 | 0.100 |
Why?
|
| Cyclin D1 | 2 | 2018 | 59 | 0.100 |
Why?
|
| Cell Membrane | 3 | 2010 | 233 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2014 | 121 | 0.100 |
Why?
|
| Indole Alkaloids | 1 | 2012 | 1 | 0.100 |
Why?
|
| Apocynaceae | 1 | 2012 | 1 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 146 | 0.100 |
Why?
|
| Sulfhydryl Compounds | 1 | 2012 | 17 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 271 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 302 | 0.100 |
Why?
|
| Intestines | 1 | 2014 | 159 | 0.100 |
Why?
|
| Phytotherapy | 1 | 2012 | 45 | 0.100 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 313 | 0.100 |
Why?
|
| Pain Measurement | 4 | 2017 | 259 | 0.100 |
Why?
|
| Polyamines | 1 | 2012 | 8 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2012 | 46 | 0.090 |
Why?
|
| Transcriptome | 1 | 2015 | 367 | 0.090 |
Why?
|
| Alcoholism | 2 | 2012 | 242 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2012 | 350 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2012 | 90 | 0.090 |
Why?
|
| Disease Progression | 3 | 2013 | 880 | 0.090 |
Why?
|
| Half-Life | 3 | 2007 | 86 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 72 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 39 | 0.090 |
Why?
|
| Vincristine | 1 | 2012 | 89 | 0.090 |
Why?
|
| Pain Threshold | 3 | 2018 | 40 | 0.090 |
Why?
|
| Sulindac | 2 | 2013 | 2 | 0.090 |
Why?
|
| Amino Acids | 1 | 2014 | 382 | 0.090 |
Why?
|
| Swine | 2 | 2010 | 440 | 0.090 |
Why?
|
| Alkynes | 1 | 2011 | 6 | 0.090 |
Why?
|
| Algorithms | 4 | 2009 | 667 | 0.090 |
Why?
|
| Chromones | 1 | 2011 | 16 | 0.090 |
Why?
|
| Norepinephrine | 2 | 2009 | 106 | 0.090 |
Why?
|
| Administration, Mucosal | 1 | 2011 | 1 | 0.090 |
Why?
|
| Mucociliary Clearance | 1 | 2011 | 3 | 0.090 |
Why?
|
| Indolizines | 1 | 2011 | 5 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 3 | 2008 | 193 | 0.090 |
Why?
|
| Plasma Membrane Neurotransmitter Transport Proteins | 2 | 2008 | 3 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2017 | 228 | 0.090 |
Why?
|
| Administration, Intranasal | 1 | 2011 | 30 | 0.090 |
Why?
|
| Libraries, Digital | 1 | 2011 | 2 | 0.090 |
Why?
|
| Middle Aged | 6 | 2009 | 13419 | 0.080 |
Why?
|
| Gels | 1 | 2011 | 22 | 0.080 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 4 | 2013 | 8 | 0.080 |
Why?
|
| Enzyme Activation | 4 | 2014 | 267 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 4 | 2013 | 169 | 0.080 |
Why?
|
| Benzopyrans | 1 | 2010 | 11 | 0.080 |
Why?
|
| Tetracycline | 1 | 2010 | 24 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2011 | 47 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2010 | 174 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 227 | 0.080 |
Why?
|
| Proteins | 2 | 2023 | 351 | 0.080 |
Why?
|
| Adult | 6 | 2009 | 14534 | 0.080 |
Why?
|
| Hydroquinones | 1 | 2010 | 3 | 0.080 |
Why?
|
| Hydrogenation | 1 | 2010 | 3 | 0.080 |
Why?
|
| Norbornanes | 1 | 2010 | 3 | 0.080 |
Why?
|
| Plant Extracts | 1 | 2012 | 200 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 83 | 0.080 |
Why?
|
| Myeloablative Agonists | 1 | 2010 | 32 | 0.080 |
Why?
|
| Diffusion | 5 | 2009 | 11 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2012 | 490 | 0.080 |
Why?
|
| Acetates | 2 | 2007 | 51 | 0.080 |
Why?
|
| Microwaves | 1 | 2009 | 10 | 0.080 |
Why?
|
| United States | 4 | 2008 | 5409 | 0.080 |
Why?
|
| Dextromethorphan | 1 | 2009 | 16 | 0.080 |
Why?
|
| Urethane | 1 | 2009 | 5 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 107 | 0.080 |
Why?
|
| Glutamate-Cysteine Ligase | 2 | 2013 | 20 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 167 | 0.080 |
Why?
|
| Protein Disulfide Reductase (Glutathione) | 1 | 2009 | 2 | 0.080 |
Why?
|
| Electrophysiology | 2 | 2008 | 60 | 0.080 |
Why?
|
| Kidney | 1 | 2014 | 715 | 0.070 |
Why?
|
| Conditioning, Operant | 3 | 2018 | 104 | 0.070 |
Why?
|
| Ventral Tegmental Area | 1 | 2009 | 8 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2009 | 25 | 0.070 |
Why?
|
| Proteinuria | 1 | 2009 | 38 | 0.070 |
Why?
|
| Cattle | 2 | 2007 | 207 | 0.070 |
Why?
|
| Nociception | 2 | 2019 | 12 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 128 | 0.070 |
Why?
|
| Aldehydes | 1 | 2009 | 81 | 0.070 |
Why?
|
| Water | 1 | 2009 | 87 | 0.070 |
Why?
|
| Glass | 1 | 2008 | 4 | 0.070 |
Why?
|
| Adsorption | 1 | 2008 | 18 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2009 | 571 | 0.070 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2008 | 1 | 0.070 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2008 | 13 | 0.070 |
Why?
|
| Skin Physiological Phenomena | 1 | 2008 | 16 | 0.070 |
Why?
|
| Surface Properties | 1 | 2008 | 61 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2008 | 502 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 158 | 0.070 |
Why?
|
| Liver | 1 | 2014 | 1150 | 0.070 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 56 | 0.070 |
Why?
|
| Tromethamine | 1 | 2007 | 3 | 0.070 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2007 | 9 | 0.070 |
Why?
|
| Maternal Exposure | 1 | 2008 | 103 | 0.070 |
Why?
|
| Aerosols | 1 | 2008 | 74 | 0.070 |
Why?
|
| Thiazolidines | 1 | 2007 | 5 | 0.070 |
Why?
|
| Biological Transport, Active | 2 | 2008 | 29 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2008 | 82 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 59 | 0.070 |
Why?
|
| Guanidine | 1 | 2007 | 3 | 0.070 |
Why?
|
| Hippocampus | 1 | 2009 | 195 | 0.070 |
Why?
|
| Seizures | 1 | 2009 | 203 | 0.070 |
Why?
|
| Pregnanes | 1 | 2007 | 3 | 0.070 |
Why?
|
| Hydrogen | 1 | 2007 | 14 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 40 | 0.070 |
Why?
|
| Allosteric Regulation | 3 | 2013 | 16 | 0.070 |
Why?
|
| Semicarbazones | 1 | 2007 | 1 | 0.070 |
Why?
|
| Motion Sickness | 1 | 2007 | 7 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 55 | 0.070 |
Why?
|
| Calibration | 1 | 2007 | 58 | 0.070 |
Why?
|
| Tablets | 1 | 2007 | 32 | 0.070 |
Why?
|
| Membranes, Artificial | 2 | 2023 | 15 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 579 | 0.060 |
Why?
|
| Oxidation-Reduction | 3 | 2013 | 333 | 0.060 |
Why?
|
| Extracellular Fluid | 1 | 2006 | 14 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 44 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 64 | 0.060 |
Why?
|
| Permeability | 4 | 2010 | 70 | 0.060 |
Why?
|
| Hydrolysis | 1 | 2006 | 67 | 0.060 |
Why?
|
| Xenopus laevis | 3 | 2013 | 44 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 412 | 0.060 |
Why?
|
| Crystallography | 1 | 2006 | 6 | 0.060 |
Why?
|
| Absorption | 1 | 2006 | 21 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 347 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 175 | 0.060 |
Why?
|
| Random Allocation | 3 | 2013 | 284 | 0.060 |
Why?
|
| Neostriatum | 3 | 2013 | 9 | 0.060 |
Why?
|
| Cyclization | 1 | 2005 | 5 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2012 | 1569 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 2007 | 114 | 0.060 |
Why?
|
| Plant Roots | 1 | 2005 | 26 | 0.060 |
Why?
|
| Timolol | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 3 | 2013 | 49 | 0.060 |
Why?
|
| Atenolol | 1 | 2005 | 13 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 281 | 0.060 |
Why?
|
| Synaptic Membranes | 1 | 2005 | 2 | 0.060 |
Why?
|
| Carbonates | 1 | 2005 | 3 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1112 | 0.060 |
Why?
|
| Formaldehyde | 3 | 2011 | 51 | 0.060 |
Why?
|
| Constriction, Pathologic | 3 | 2011 | 91 | 0.060 |
Why?
|
| Nitrosamines | 3 | 2011 | 8 | 0.060 |
Why?
|
| Pregnancy | 2 | 2012 | 2608 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 162 | 0.060 |
Why?
|
| Chickens | 1 | 2005 | 106 | 0.060 |
Why?
|
| Program Evaluation | 2 | 2003 | 359 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2007 | 131 | 0.060 |
Why?
|
| Butyrates | 1 | 2005 | 30 | 0.060 |
Why?
|
| X-Rays | 2 | 2017 | 55 | 0.060 |
Why?
|
| Transfection | 1 | 2005 | 359 | 0.050 |
Why?
|
| Valerates | 1 | 2005 | 39 | 0.050 |
Why?
|
| Octanols | 1 | 2004 | 1 | 0.050 |
Why?
|
| Formates | 1 | 2004 | 4 | 0.050 |
Why?
|
| Physical Stimulation | 3 | 2008 | 30 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 3494 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2004 | 36 | 0.050 |
Why?
|
| Papilloma | 1 | 2004 | 10 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 405 | 0.050 |
Why?
|
| Plants, Genetically Modified | 1 | 2004 | 19 | 0.050 |
Why?
|
| Biological Assay | 1 | 2004 | 46 | 0.050 |
Why?
|
| Carboxy-Lyases | 1 | 2003 | 2 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 233 | 0.050 |
Why?
|
| Ubiquitin | 2 | 2015 | 70 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2006 | 325 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 561 | 0.050 |
Why?
|
| Discrimination Learning | 2 | 2018 | 58 | 0.050 |
Why?
|
| Cost Control | 1 | 2003 | 13 | 0.050 |
Why?
|
| Internationality | 1 | 2004 | 46 | 0.050 |
Why?
|
| Ultrafiltration | 1 | 2023 | 6 | 0.050 |
Why?
|
| Dialysis Solutions | 1 | 2023 | 3 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2006 | 278 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2003 | 32 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 73 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2004 | 78 | 0.050 |
Why?
|
| Yersinia pestis | 1 | 2003 | 21 | 0.050 |
Why?
|
| Alkylation | 2 | 2019 | 9 | 0.050 |
Why?
|
| Sirolimus | 2 | 2016 | 72 | 0.050 |
Why?
|
| Urea | 1 | 2023 | 80 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2004 | 121 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 23 | 0.050 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2004 | 61 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2003 | 38 | 0.050 |
Why?
|
| Carcinogens | 3 | 2011 | 194 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 274 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2015 | 363 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2004 | 124 | 0.050 |
Why?
|
| Immunotoxins | 1 | 2002 | 6 | 0.050 |
Why?
|
| Electric Stimulation | 2 | 2016 | 103 | 0.050 |
Why?
|
| Radiation, Ionizing | 1 | 2003 | 101 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2002 | 45 | 0.050 |
Why?
|
| Young Adult | 2 | 2009 | 4511 | 0.050 |
Why?
|
| Medicare | 1 | 2004 | 280 | 0.040 |
Why?
|
| Chemical Phenomena | 2 | 2014 | 13 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2021 | 42 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2021 | 27 | 0.040 |
Why?
|
| Gamma Rays | 2 | 2015 | 48 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 163 | 0.040 |
Why?
|
| Thioredoxins | 2 | 2013 | 26 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 152 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2913 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2008 | 563 | 0.040 |
Why?
|
| Sumoylation | 1 | 2020 | 21 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 2 | 2013 | 105 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2013 | 22 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 759 | 0.040 |
Why?
|
| Electrochemistry | 2 | 2013 | 23 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 60 | 0.040 |
Why?
|
| Adolescent | 2 | 2009 | 6907 | 0.040 |
Why?
|
| X-Ray Diffraction | 1 | 2020 | 11 | 0.040 |
Why?
|
| Densitometry | 1 | 2020 | 13 | 0.040 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 25 | 0.040 |
Why?
|
| Tensile Strength | 1 | 2020 | 31 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 35 | 0.040 |
Why?
|
| Aged | 3 | 2009 | 10429 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2002 | 726 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 477 | 0.040 |
Why?
|
| Infant | 1 | 2008 | 3805 | 0.040 |
Why?
|
| Cytokines | 2 | 2013 | 627 | 0.040 |
Why?
|
| Catalepsy | 1 | 2019 | 9 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 975 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 500 | 0.040 |
Why?
|
| Cyclin A | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cell Movement | 2 | 2010 | 279 | 0.040 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 122 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 32 | 0.040 |
Why?
|
| Mesocricetus | 2 | 2008 | 6 | 0.040 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2018 | 5 | 0.030 |
Why?
|
| Streptozocin | 1 | 2018 | 25 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2018 | 105 | 0.030 |
Why?
|
| Postural Balance | 2 | 2008 | 59 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2008 | 60 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 2018 | 71 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2010 | 289 | 0.030 |
Why?
|
| Cyclohexanols | 1 | 2017 | 20 | 0.030 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2017 | 13 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2013 | 315 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2017 | 68 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2017 | 58 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2018 | 168 | 0.030 |
Why?
|
| Cocaine | 2 | 2011 | 168 | 0.030 |
Why?
|
| Prostate | 1 | 2017 | 118 | 0.030 |
Why?
|
| NADP | 1 | 2016 | 23 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 2016 | 35 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2016 | 15 | 0.030 |
Why?
|
| Phosphoserine | 1 | 2016 | 5 | 0.030 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2016 | 6 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 128 | 0.030 |
Why?
|
| Progesterone | 1 | 2016 | 57 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 109 | 0.030 |
Why?
|
| Child | 1 | 2008 | 7379 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 211 | 0.030 |
Why?
|
| DNA | 2 | 2010 | 535 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 3082 | 0.030 |
Why?
|
| Turtles | 1 | 2015 | 1 | 0.030 |
Why?
|
| Centrosome | 1 | 2015 | 11 | 0.030 |
Why?
|
| Cholinergic Antagonists | 1 | 2015 | 4 | 0.030 |
Why?
|
| Bungarotoxins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Cholinergic Agonists | 1 | 2015 | 10 | 0.030 |
Why?
|
| Virus Replication | 1 | 2016 | 149 | 0.030 |
Why?
|
| Rubidium | 2 | 2005 | 4 | 0.030 |
Why?
|
| Transition Temperature | 2 | 2005 | 6 | 0.030 |
Why?
|
| Phenotype | 1 | 2018 | 803 | 0.030 |
Why?
|
| Taxoids | 1 | 2014 | 38 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 456 | 0.030 |
Why?
|
| Biotransformation | 2 | 2005 | 84 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 298 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 71 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 45 | 0.030 |
Why?
|
| Drug Inverse Agonism | 1 | 2014 | 18 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2015 | 187 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2016 | 268 | 0.030 |
Why?
|
| Microsomes | 1 | 2014 | 35 | 0.030 |
Why?
|
| Chromatin | 1 | 2015 | 145 | 0.030 |
Why?
|
| Dopa Decarboxylase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2013 | 23 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2013 | 10 | 0.030 |
Why?
|
| Reserpine | 1 | 2013 | 13 | 0.030 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2013 | 5 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 54 | 0.030 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2013 | 14 | 0.030 |
Why?
|
| Microdialysis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2013 | 37 | 0.030 |
Why?
|
| Cytotoxins | 1 | 2013 | 15 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2013 | 16 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 18 | 0.030 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2013 | 15 | 0.030 |
Why?
|
| Zebrafish | 1 | 2013 | 61 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 426 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 76 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2013 | 16 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 69 | 0.020 |
Why?
|
| Medicine, African Traditional | 1 | 2012 | 2 | 0.020 |
Why?
|
| 3T3-L1 Cells | 1 | 2012 | 13 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 86 | 0.020 |
Why?
|
| Seeds | 1 | 2012 | 21 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2013 | 51 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2013 | 56 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 90 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 69 | 0.020 |
Why?
|
| NAD | 1 | 2012 | 45 | 0.020 |
Why?
|
| Patents as Topic | 1 | 2012 | 10 | 0.020 |
Why?
|
| Drug-Seeking Behavior | 1 | 2012 | 4 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 318 | 0.020 |
Why?
|
| DNA Replication | 1 | 2013 | 161 | 0.020 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 102 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 184 | 0.020 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2011 | 5 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 218 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 373 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 229 | 0.020 |
Why?
|
| Food | 1 | 2011 | 69 | 0.020 |
Why?
|
| Vero Cells | 1 | 2011 | 40 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 264 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 76 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 202 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 21 | 0.020 |
Why?
|
| Rotarod Performance Test | 1 | 2010 | 5 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 2010 | 15 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 214 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2011 | 84 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2010 | 2 | 0.020 |
Why?
|
| Glucose | 1 | 2012 | 361 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 24 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 90 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 2010 | 34 | 0.020 |
Why?
|
| Fungi | 1 | 2010 | 51 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2010 | 12 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 180 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 92 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 620 | 0.020 |
Why?
|
| Cations | 1 | 2009 | 9 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 168 | 0.020 |
Why?
|
| Gastrointestinal Motility | 1 | 2010 | 50 | 0.020 |
Why?
|
| Catalase | 1 | 2010 | 72 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 104 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 163 | 0.020 |
Why?
|
| Proteomics | 1 | 2012 | 336 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 411 | 0.020 |
Why?
|
| Drug Partial Agonism | 1 | 2009 | 6 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2010 | 180 | 0.020 |
Why?
|
| Cell Shape | 1 | 2009 | 21 | 0.020 |
Why?
|
| Pyrazines | 1 | 2010 | 188 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 120 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 32 | 0.020 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2009 | 7 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 26 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 321 | 0.020 |
Why?
|
| Chemokines, C | 1 | 2008 | 1 | 0.020 |
Why?
|
| Mucins | 1 | 2008 | 8 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 1925 | 0.020 |
Why?
|
| Stereotyped Behavior | 1 | 2008 | 16 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2008 | 43 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 359 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 57 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 393 | 0.020 |
Why?
|
| Chemistry, Physical | 1 | 2008 | 6 | 0.020 |
Why?
|
| Skin Irritancy Tests | 1 | 2008 | 3 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2008 | 85 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2010 | 350 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 175 | 0.020 |
Why?
|
| Reaction Time | 1 | 2008 | 207 | 0.020 |
Why?
|
| Alcohol-Related Disorders | 1 | 2008 | 44 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 202 | 0.020 |
Why?
|
| Vitreous Body | 1 | 2007 | 19 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2007 | 25 | 0.020 |
Why?
|
| Sucrose | 1 | 2007 | 24 | 0.020 |
Why?
|
| Dogs | 1 | 2007 | 186 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2007 | 58 | 0.020 |
Why?
|
| Insecticides | 1 | 2007 | 17 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 66 | 0.020 |
Why?
|
| RNA | 1 | 2008 | 173 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 934 | 0.020 |
Why?
|
| Static Electricity | 1 | 2006 | 22 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2007 | 31 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1133 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 1337 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2007 | 60 | 0.020 |
Why?
|
| Amphetamine | 1 | 2006 | 36 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2009 | 333 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 135 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 171 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 652 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 370 | 0.010 |
Why?
|
| Nomifensine | 1 | 2005 | 2 | 0.010 |
Why?
|
| Solvents | 1 | 2005 | 32 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 56 | 0.010 |
Why?
|
| Hemicholinium 3 | 1 | 2005 | 3 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 228 | 0.010 |
Why?
|
| Acetylation | 1 | 2005 | 97 | 0.010 |
Why?
|
| Mineral Oil | 1 | 2005 | 4 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 547 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 465 | 0.010 |
Why?
|
| Catheterization | 1 | 2006 | 95 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 76 | 0.010 |
Why?
|
| Caproates | 1 | 2005 | 2 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 191 | 0.010 |
Why?
|
| Propionates | 1 | 2005 | 23 | 0.010 |
Why?
|
| Abdomen | 1 | 2005 | 71 | 0.010 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2004 | 6 | 0.010 |
Why?
|
| Paraquat | 1 | 2004 | 5 | 0.010 |
Why?
|
| Teratogens | 1 | 2004 | 8 | 0.010 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2004 | 8 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2004 | 77 | 0.010 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2004 | 8 | 0.010 |
Why?
|
| Epidermis | 1 | 2004 | 32 | 0.010 |
Why?
|
| Symporters | 1 | 2004 | 15 | 0.010 |
Why?
|
| Rabies virus | 1 | 2004 | 4 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2004 | 33 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2004 | 34 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 423 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 2003 | 3 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 36 | 0.010 |
Why?
|
| Catalysis | 1 | 2003 | 87 | 0.010 |
Why?
|
| Lung | 1 | 2007 | 481 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2004 | 106 | 0.010 |
Why?
|
| Membranes | 1 | 2003 | 15 | 0.010 |
Why?
|
| Thrombosis | 1 | 2006 | 250 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 489 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 180 | 0.010 |
Why?
|
| Perfusion | 1 | 2002 | 49 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2003 | 404 | 0.010 |
Why?
|